vs
CAMDEN NATIONAL CORP（CAC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CAMDEN NATIONAL CORP的2.0倍（$127.1M vs $64.3M），过去两年CAMDEN NATIONAL CORP的营收复合增速更高（22.6% vs 20.8%）
卡姆登国民银行是一家总部位于美国缅因州卡姆登的商业银行，是上市银行控股公司卡姆登国民集团的核心子公司。该行创立于1875年，1984年完成企业重组后成为控股公司直接持有的全资子公司。2025年与诺斯韦金融合并后，合并后机构总资产约为70亿美元。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CAC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的2.0倍
$64.3M
两年增速更快
CAC
近两年复合增速
20.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.3M | $127.1M |
| 净利润 | $21.9M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 34.0% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $1.29 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CACZLAB
| Q1 26 | $64.3M | — | ||
| Q4 25 | $68.1M | $127.1M | ||
| Q3 25 | $65.4M | $115.4M | ||
| Q2 25 | $62.3M | $109.1M | ||
| Q1 25 | $60.1M | $105.7M | ||
| Q4 24 | $47.6M | $108.5M | ||
| Q3 24 | $45.0M | $101.8M | ||
| Q2 24 | $42.8M | $100.1M |
净利润CACZLAB
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | — | ||
| Q3 25 | $21.2M | $-36.0M | ||
| Q2 25 | $14.1M | $-40.7M | ||
| Q1 25 | $7.3M | $-48.4M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $13.1M | $-41.7M | ||
| Q2 24 | $12.0M | $-80.3M |
毛利率CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | -54.6% | ||
| Q3 25 | 40.5% | -42.3% | ||
| Q2 25 | 28.5% | -50.3% | ||
| Q1 25 | 10.3% | -53.3% | ||
| Q4 24 | 38.7% | -62.6% | ||
| Q3 24 | 35.2% | -66.6% | ||
| Q2 24 | 34.7% | -76.0% |
净利率CACZLAB
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | — | ||
| Q3 25 | 32.4% | -31.2% | ||
| Q2 25 | 22.6% | -37.3% | ||
| Q1 25 | 12.2% | -45.8% | ||
| Q4 24 | 30.8% | — | ||
| Q3 24 | 29.1% | -40.9% | ||
| Q2 24 | 28.0% | -80.2% |
每股收益（稀释后）CACZLAB
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | $-0.05 | ||
| Q3 25 | $1.25 | $-0.03 | ||
| Q2 25 | $0.83 | $-0.04 | ||
| Q1 25 | $0.43 | $-0.04 | ||
| Q4 24 | $1.00 | $-0.09 | ||
| Q3 24 | $0.90 | $-0.04 | ||
| Q2 24 | $0.81 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $514.4M | — |
| 股东权益账面价值 | $710.0M | $715.5M |
| 总资产 | $7.0B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M |
总债务CACZLAB
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CACZLAB
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | $715.5M | ||
| Q3 25 | $676.4M | $759.9M | ||
| Q2 25 | $652.1M | $791.7M | ||
| Q1 25 | $640.1M | $810.8M | ||
| Q4 24 | $531.2M | $840.9M | ||
| Q3 24 | $529.9M | $667.7M | ||
| Q2 24 | $508.3M | $704.2M |
总资产CACZLAB
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | $1.2B | ||
| Q3 25 | $7.0B | $1.2B | ||
| Q2 25 | $6.9B | $1.2B | ||
| Q1 25 | $7.0B | $1.2B | ||
| Q4 24 | $5.8B | $1.2B | ||
| Q3 24 | $5.7B | $985.3M | ||
| Q2 24 | $5.7B | $987.4M |
负债/权益比CACZLAB
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | $63.9M | $-26.0M | ||
| Q3 25 | $36.1M | $-32.0M | ||
| Q2 25 | $6.0M | $-31.0M | ||
| Q1 25 | $1.0M | $-61.7M | ||
| Q4 24 | $60.9M | $-55.8M | ||
| Q3 24 | $-14.5M | $-26.8M | ||
| Q2 24 | $14.5M | $-42.2M |
自由现金流CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | $-26.7M | ||
| Q3 25 | $35.4M | $-35.0M | ||
| Q2 25 | $4.5M | $-33.9M | ||
| Q1 25 | $-727.0K | $-63.2M | ||
| Q4 24 | $55.4M | $-58.4M | ||
| Q3 24 | $-16.2M | $-28.2M | ||
| Q2 24 | $13.2M | $-42.9M |
自由现金流率CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | 85.5% | -21.0% | ||
| Q3 25 | 54.1% | -30.4% | ||
| Q2 25 | 7.3% | -31.1% | ||
| Q1 25 | -1.2% | -59.9% | ||
| Q4 24 | 116.4% | -53.8% | ||
| Q3 24 | -36.0% | -27.7% | ||
| Q2 24 | 30.8% | -42.9% |
资本支出强度CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | 8.4% | 0.5% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 2.9% | 1.5% | ||
| Q4 24 | 11.7% | 2.4% | ||
| Q3 24 | 3.8% | 1.3% | ||
| Q2 24 | 3.0% | 0.7% |
现金转化率CACZLAB
| Q1 26 | — | — | ||
| Q4 25 | 2.83× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 4.15× | — | ||
| Q3 24 | -1.11× | — | ||
| Q2 24 | 1.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
